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1. Introduction 
This chapter will review the roles of protein kinase C (PKC) isozymes in chronic 
lymphocytic leukaemia (CLL) cells. PKC family proteins are central to many signalling 
pathways within cells, and some have been implicated in the oncogenesis of numerous 
cancers (Benimetskaya, et al., 2001;Keenan, et al., 1999;O'Brian, 1998). In CLL, inhibitors of 
PKC signalling have been shown to have cytotoxic effects on the malignant cells, and the 
,  and  isoforms of PKC have been shown to have pathophysiological roles (Holler, et 
al., 2009;Nakagawa, et al., 2006;Ringshausen, et al., 2002).  The aim of this chapter is to 
discuss whether PKC can be considered a drug target in the treatment of this disease. We 
will examine how inhibitors of PKCs have been used in past preclinical studies of CLL, 
and will discuss the roles of various PKC isozymes (namely PKCII, PKC, PKC and 
PKC) in the pathology of CLL. This chapter will end with the proposal that inhibition of 
PKC may be useful in combination therapy through a potential role in regulating Mcl-1 
expression. 
2. PKC in CLL 
Survival and expansion of the malignant clone in CLL involves a myriad of intrinsic and 
extrinsic signals and most, if not all of these signals will involve the kinase function of PKC. 
For example, chronic antigen stimulation of the B-cell receptor (BCR) is thought to play a 
key role in CLL cell survival (Chiorazzi, et al., 2005), and the  isoform of PKC (PKC) is 
known to play an important role in BCR signalling (Kang, et al., 2001;Saijo, et al., 2002). In 
this context, specific targeting of PKC in CLL cells may either enhance or inhibit the pro-
survival signals that BCR engagement provides. 
A role for PKC function in CLL cell survival was first suggested in experiments using 
PKC agonists such as the phorbol ester 12-0 tetradecanoylphorbol 13-acetate (TPA) and 
bryostatin (al-Katib, et al., 1993;Drexler, et al., 1989;Forbes, et al., 1992;Totterman, et al., 
1980).  These compounds are natural product analogues of diacylglycerol, which is the 
ligand of PKC within cells, and act to stimulate kinase activity of PKC. Initial 
observations showed that treatment of CLL cells with either TPA or bryostatin-1 resulted 
in the induction of differentiation and inhibition of spontaneous apoptosis (al-Katib, et 
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al., 1993;Barragan, et al., 2002;Drexler, et al., 1989;Forbes, et al., 1992;Totterman, et al., 
1980;Varterasian, et al., 2000). Exploration of the mechanism through which TPA and 
bryostatin induced CLL cell differentiation showed that this was likely due to PKC-
mediated activation of the ERK pathway (Figure 1A). These early experiments prompted 
a phase I (Varterasian, et al., 1998) and phase II (Varterasian, et al., 2000) clinical trial of 
bryostatin in CLL. The findings of these studies showed that bryostatin could induce in 
vivo differentiation of the malignant cells in CLL patients (Varterasian, et al., 2000). 
Combination of bryostatin with 2-chlorodeoxyadenosine showed promise in treating 
CLL in both an animal model of CLL (Mohammad, et al., 1998) as well as a case report of 
a single patient (Ahmad, et al., 2000), however, the use of bryostatin as a therapeutic 
agent has not been followed up. This could be because other studies have shown that 
TPA and bryostatin provide protection against dexamethasone- and fludarabine-induced 
apoptosis of CLL cells (Bellosillo, et al., 1997;Kitada, et al., 1999). Investigation of the 
mechanism through which this protection is provided showed that these compounds 
stimulate upregulation of the anti-apoptotic proteins Mcl-1 and XIAP (Thomas, et al., 
2004) (Figure 1A). 
A second approach to address the role of PKC in CLL cell survival has used inhibitors of 
this enzyme. Thus, compounds such as UCN01 (Byrd, et al., 2001;Kitada, et al., 2000), 
PKC412 (Ganeshaguru, et al., 2002), LY379196 (Abrams, et al., 2007) and Bisindolymaleimide 
(Barragan, et al., 2002;Snowden, et al., 2003) have all been shown to potently induce 
apoptosis of CLL cells in vitro. Interestingly, treatment of CLL cells with UCN01 or 
Bisindolylmaleimide reduces the expression of Mcl-1 and XIAP (Kitada, et al., 
2000;Snowden, et al., 2003), thereby making treated cells more susceptible to apoptosis 
(Figure 1B).  This observation, when taken together with others showing that activation of 
PKC results in an upregulation of Mcl-1 and XIAP, strongly suggest that PKC is an 
important mediator of CLL cell survival signals. 
Bryostatin/TPA
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Differentiation
Mcl-1
Apoptotic resistance
UCN01/BisindolymaleimideA B
XIAP Mcl-1 XIAP
Apoptosis
 
Fig. 1. Effects of PKC agonists and antagonists on CLL cells. (A) PKC agonists such as TPA 
and bryostatin induce ERK-mediated differentiation in CLL cells, and inhibit spontaneous 
apoptosis by stimulating the expression of Mcl-1 and XIAP. (B) PKC antagonists such as 
UCN01 or Bisindolymaleimide reduce the expression of Mcl-1 and XIAP in CLL cells 
thereby increasing the potential of CLL cells to undergo apoptosis.  
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2.1 PKC structure and function 
PKCs are a family of serine/threonine kinases that share extensive structural homologies 
between different isotypes. Despite this homology, PKCs regulate different cellular 
functions in a variety of cell types, including proliferation, differentiation, apoptosis and cell 
survival (Tan & Parker, 2003). PKCs are divided into three subfamilies based on their 
regulatory domain composition, which determines what co-factors help induce their 
activation.  Classical PKCs (PKC, I, II, and ) require the presence of DAG and calcium 
for activation, while novel PKCs (PKC , , , ) require only the presence of DAG. In 
contrast, atypical PKCs (PKC , /) are both calcium and diacylglycerol-independent 
(Mellor & Parker, 1998).  
The structure of all PKC family members is comprised of a C-terminal kinase domain linked 
by a flexible hinge segment to an N-terminal regulatory domain (Parker & Murray-Rust, 
2004) (Figure 2). The kinase domain of PKC is highly conserved among isoforms and shows 
homology to the AGC superfamily of serine/threonine protein kinases. This domain 
contains the ATP- and substrate-binding sites, and also serves as a phosphorylation-
dependent docking site for the regulatory molecules that interact with PKC (Newton, 2010). 
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Fig. 2. Schematic representation of PKC isoform structure. The regulatory domain of PKC 
isoforms contain the regions necessary for membrane association and activation of the 
kinase. The C1 domain binds DAG/phorbol esters, and also contains a pseudosubstrate (PS) 
sequence at its N-terminus. The PS binds to the substrate-binding site within the catalytic 
domain to hold PKC in an inactive state. Atypical PKCs have a unique C1 region (C1 AT) as 
well as a Phox and Bem1 (PB1) region which are likely responsible for protein interaction 
resulting in kinase activation. The C2 domain regulates Ca2+-mediated phospholipid 
binding in classical PKCs. Novel PKCs have a C2-like domain that does not bind Ca2+ (C2 
N). The catalytic domain of all PKCs is conserved and contains the regions necessary for 
ATP-binding (the C3 domain) and for binding to substrate (the C4 domain). A PDZ region is 
also present in some PKC isoforms, and is responsible for protein-protein interactions 
following kinase activation. 
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The regulatory domain of PKC is divided into two regions. At the N-terminus there is a 
pseudosubstrate (PS) sequence that is responsible for binding the catalytic domain and 
maintaining the enzyme in an inactive conformation when it is in the cytoplasm (House & 
Kemp, 1987). This domain of PKC also contains the regions responsible for membrane 
targeting. Thus,  classical PKCs contain motifs, termed C1 domains, that are able to bind 
DAG as well as phorbol esters (Newton, 1995a). Classical PKCs also have motifs, termed C2 
domains, that are responsible for binding membrane phospholipids such as 
phosphatidylserine (PtS) and phosphatidylinositol-4-5-biphosphate (PIP2) in a Ca2+-
dependent manner (Newton, 1995a). Novel and atypical PKC isoforms have a different 
regulatory domain structure. Novel PKCs contain tandem C1 domains that bind DAG with 
an affinity that is high enough to induce translocation to the membrane (Giorgione, et al., 
2006), and use a C2-like domain to bind phospholipids in a Ca2+-independent manner 
(Newton, 1995a). In contrast, atypical PKCs lack a C2 domain in any format, and contain an 
impaired C1 domain that does not bind diacylglycerol (Newton, 1995a). Instead, atypical 
PKC isoforms depend largely upon protein-protein interactions for activation. For this 
purpose, these isoforms contain an N-terminal PB1 domain and a C-terminal PDZ ligand 
binding domain. 
The flexible hinge region of PKCs is important in as much as it allows the close apposition of 
the regulatory and catalytic domains when PKC is in an inactive state. When PKC becomes 
activated, the hinge region allows the protein to unfold to the extent needed for the catalytic 
domain to interact with substrates and regulatory proteins. 
2.2 PKC regulation 
PKC is regulated by four key mechanisms: phosphorylation, co-factor binding, protein-
protein interactions and regulated degradation. All help regulate the subcellular 
localisation, structure, and function of the enzyme.  
2.2.1 Processing of PKC  
Newly synthesised PKC is associated with membrane fractions where it is processed by a 
series of tightly coupled phosphorylations on serine and/or threonine residues in the 
catalytic domain (Newton, 2010) (Figure 3). These phosphorylations are essential before 
PKC can become activated, and the series in which they take place is analogous to other 
AGC protein kinases such as Akt. The binding of the chaperone protein heat shock protein 
90 (HSP90) was identified as an initial step in the maturation of both classical and novel 
PKC isoforms (Gould, et al., 2009). It binds to the catalytic domain of PKC and primes the 
enzyme for phosphorylation within the activation loop of the catalytic domain (Figure 3A). 
Failure of PKC to bind HSP90 results in inhibited phosphorylation at this site, misfolding of 
the entire protein and its consequent degradation (Balendran, et al., 2000;Gould, et al., 2009). 
Phosphorylation of the activation loop of PKC is catalyzed by 3-phosphoinositide-
dependent kinase (PDK)-1, which binds to the exposed C-terminus of newly synthesised 
PKC that is in complex with HSP90 (Chou, et al., 1998;Dutil, et al., 1998;Dutil & Newton, 
2000) (Figure 3A). This is followed by phosphorylation of the turn motif by the mTORC2 
complex (Ikenoue, et al., 2008) (Figure 3B). Phosphorylation of the turn motif stabilises the 
active conformation of PKC prior to autophosphorylation of the hydrophobic motif and 
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generation of catalytically competent PKC (Behn-Krappa & Newton, 1999). Whether this 
latter step results from autophosphorylation is controversial because phosphorylation of the 
hydrophobic motif does not take place  in mTORC2 deficient cells (Newton, 2010).  
However, because phosphorylation of the turn motif must take place before 
phosphorylation of the hydrophobic motif, it is likely to be very difficult to fully define the 
kinase(s) responsible. It is important to note here that phosphorylation of the activation 
loop, turn and hydrophobic motifs within PKC only results in an enzyme that is fully 
matured and catalytically competent, it should not be mistaken for active PKC as these sites 
will be phosphorylated on inactive PKC located within the cytoplasm of cells. 
2.2.2 Mechanism(s) of activation 
Fully matured PKC is predominantly localised to the cytosol, where it is likely maintained 
in specific microenvironments by interacting with regulatory proteins (Schechtman & 
Mochly-Rosen, 2001).  Here, the enzyme is held in an inactive conformation by the N-
terminal PS binding to the substrate-binding site of the catalytic domain (House & Kemp, 
1987). Processes that result in a structural change in the protein so that the N-terminus of 
PKC is no longer in close proximity to the C-terminus result in activation of the enzyme. 
Typically, activation of classical isoforms of PKC occurs following the induction of PIP2 
hydrolysis within certain pathways of intracellular signalling. This generates Ca2+ and DAG, 
two second messengers crucial for the activation of classical PKCs (Beaven, 1996;Nishizuka, 
1988). Ca2+ binds to the C2 domain of classical PKCs causing their translocation to the 
plasma membrane where they bind phospholipids such as PtS and PIP2 (Cho, 2001;Newton, 
1995b) (Figure 3C). Once at the membrane the C1 domain of PKC binds to membrane-bound 
DAG, an interaction aided by the binding of PtS (Bolsover, et al., 2003;Cho, 2001). The 
engagement of both the C1 and C2 domains then causes a structural change in PKC that 
induces the release of the PS from the substrate-binding site of the catalytic domain, freeing 
PKC to catalyze the phosphorylation of downstream substrates (Newton, 1995a).  The 
greater affinity of the C1 domain of novel PKC isoforms for DAG (Giorgione, et al., 2006) 
allows the recruitment of these isoforms to membranes without the need for Ca2+. Once at 
the membrane, novel PKC isozymes, like classical ones, unfold the regulatory domains from 
the catalytic domains and kinase activities ensue. 
However, there are additional mechanisms of activation involving post-translational 
modification. Tyrosine kinases such as pp60src are able to bind some PKC isoforms, such 
as PKC, and catalyze their tyrosine phosphorylation (Joseloff, et al., 2002;Kronfeld, et al., 
2000;Yuan, et al., 1998). Phosphorylated tyrosine residues within PKC then act as docking 
sites for SH2 domain-containing proteins, which can further regulate the function of this 
PKC isoform (Leitges, et al., 2002). The specific tyrosine residue where phosphorylation 
occurs dictates the response induced by PKC. The location of this phosphorylation and 
resultant cellular response is largely dependent upon the inciting stimulus and cell type. 
For example, the use of a mutant form of PKC containing several tyrosine residue 
mutations found that phosphorylation of Y64 and Y187 were important sites for regulating 
etoposide-induced apoptosis in C6 glioma cells (Blass, et al., 2002). In contrast, viral 
infection of PC12 cells induced the phosphorylation of Y52, Y64 and Y155 in PKC and these 
sites proved essential in mediating the antiapoptotic effects of this PKC isoform (Wert & 
Palfrey, 2000).  
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Fig. 3. PKC regulation (adapted from Newton, et al., 2010). (A) HSP90 binds the kinase 
domain of newly synthesised PKC within the C3 region and primes it for phosphorylation 
of the activation motif by PDK-1. (B) mTORC2 and/or autophosphorylation is then 
responsible for phosphorylating the turn and then hydrophobic motifs within the C4 
region of the catalytic domain. This results in fully-matured PKC which is then 
maintained in different cytosolic locations by interacting with scaffold proteins, and in an 
inactive state through interaction of the pseudosubstrate (PS) in the C1 region of the 
regulatory domain with the substrate binding site (C4) in the catalytic domain. (C) 
Specific stimuli induce the production of PIP2 , DAG and Ca2+. This causes the recruitment 
of PKC to the membrane where the C1 domain binds DAG and the C2 domain binds 
phospholipids such as PIP2 and phosphotidylserine (PtS) in a Ca2+-dependant way. 
Membrane association of PKC releases the PS from the substrate-binding site to allow the 
protein to assume an active conformation and induce downstream signalling. (D) Active 
PKC is prone to dephosphorylation by phosphatases. PHLPP (PH domain leucine-rich 
repeat protein phosphatase) dephosphorylates the hydrophobic motif, while the 
activation and turn motifs are likely dephosphorylated by PP2A. (E) Dephosphorylated 
PKC is then either degraded, or HSP70 can bind the unphosphorylated turn motif and 
allow rephosphorylation of PKC to occur.  
Other examples of post-translational modification include the oxidation of cysteines within 
the C1 domain. This causes a conformational change similar to that induced by lipid binding 
to result in increased PKC activity (Knapp & Klann, 2000). This phenomenon has been 
observed for PKC, -II, - and  isoforms following exposure to superoxide anions (Knapp 
& Klann, 2000). Finally, nitrosylation of tyrosine residues can also activate certain PKC 
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isozymes. Tyrosine nitrosylation occurs in the presence of peroxynitrite and can affect PKC 
activation (Balafanova, et al., 2002). Pathologically, this is important for constitutive 
activation of ERK pathway signalling in hairy cell leukaemia cells (Slupsky, et al., 2007). 
Another mechanism of PKC activation is through the generation of an autonomous kinase 
by caspase-cleavage of the hinge domain. This form of the enzyme lacks the regulatory PS 
and is therefore maintained in an active conformation. This mechanism is best exemplified 
by PKC, which can be cleaved by caspases following the onset of apoptosis. Such cleavage 
causes the now autonomous catalytic domain of PKC to translocate to the nucleus where it 
catalyzes histone phosphorylation and chromosomal decondensation to aid in the 
production of DNA ladders that are characteristic of apoptotic cell death (Brodie & 
Blumberg, 2003;Kikkawa, et al., 2002).  
2.2.3 Co-factor binding 
The activity of all PKC isoforms is tightly coordinated by interacting with different scaffold 
proteins. These interactions help localise the enzyme to different microenvironments where 
they are in proximity to particular lipid regulators, key proteins and substrates. The C2 
(Brandman, et al., 2007) , PB1 (Hirano, et al., 2004;Moscat & Diaz-Meco, 2000) and PDZ 
(Staudinger, et al., 1997) binding domains of PKCs are specifically engineered for this 
purpose, and define the individual functions of each isozyme. Examples of such proteins 
include receptors for activated C kinase (RACKs). RACK1 and RACK2 can competitively 
bind PKC isozymes, trapping them in active conformations by relieving autoinhibition by 
the N-terminus (Ron & Mochly-Rosen, 1995). Such interactions have the potential of 
localising active PKC in areas where sustained ligand activation is not possible. PKC can 
also interact with the cytoskeleton, either directly through protein-protein interaction or by 
binding to cytoskeleton-associated proteins (Larsson, 2006). Like PKCs interaction with 
RACK proteins, these interactions can replace the need for lipid second messengers and 
induce an active PKC conformation.  
Co-factor binding to PKC can also prevent activation of this enzyme. For example, the 
overexpression of 14-3-3 in jurkat cells inhibits phorbol ester-induced PKC translocation 
from the cytosol to the membrane (Meller, et al., 1996). Taking this into consideration it is 
important to note that there are different scaffold proteins for all conformations of PKC, all 
helping to regulate PKC from the moment it is synthesised and activated, until when it is 
deactivated and degraded. 
2.2.4 Downregulation and degradation 
Despite having a long half-life in the absence of stimulation, sustained activation of PKC, 
such as that achieved when cells are treated with phorbol esters, results in its rapid 
degradation (Hansra, et al., 1999;Huang, et al., 1989;Szallasi, et al., 1994). Active PKC adopts 
a membrane-bound open conformation that is vulnerable to dephosphorylation by 
phosphatases (Dutil, et al., 1994). PH domain leucine-rich repeat protein phosphatases 
(PHLPP) are able to dephosphorylate the hydrophobic motif of novel and classical PKC 
isoforms when they are in this open membrane-bound conformation (Figure 3D). This 
dephosphorylation causes these PKC isozymes to shunt to a detergent-insoluble cell fraction 
where they are then further dephosphorylated on the turn motif, possibly by PP2A, before 
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being degraded (Brognard & Newton, 2008;Gao, et al., 2008). However, in some instances 
HSP70 can rescue PKC from this mechanism of degradation. Like HSP90, HSP70 can bind to 
the dephosphorylated turn motif of PKC and stabilise its conformation, and, in turn, 
promote its rephosphorylation and catalytic competence (Gao & Newton, 2002) (Figure 3E). 
This may be important because HSP70 is upregulated in cells undergoing stress, such as in 
response to chemotherapeutic agents (Jensen, et al., 2009).  
2.3 The role of different PKC isoforms in CLL 
To gain a greater insight into the function of PKC in CLL pathobiology it is first important to 
determine the expression profile of this enzyme in CLL cells and to define the specific role 
each isoform plays in CLL signalling. Together, these findings may help design more 
customised clinical therapies targeting specific PKC isoforms. 
2.3.1 Expression profile 
Work in our lab discovered that CLL cells express PKCI, -II, -, -, –, - and PKC / 
(Abrams, et al., 2007;Alkan, et al., 2005). Furthermore, upon comparing the expression levels 
of these isoforms to the levels expressed in normal B cells, we discovered that CLL cells 
express less PKCI and PKC, and more PKC. However, what clearly distinguished CLL 
cells from normal B cells and other B-lymphoid malignancies was an overexpression of 
PKCII equating to 0.53% ± 0.25% of total cellular protein (Abrams, et al., 2007).  
2.3.2 PKC  
The PRKCB gene is transcribed as a single mRNA that is then alternatively spliced to 
produce PKCI and PKCII (Ono, et al., 1986). In CLL cells, PKCII is the predominant 
isoform and its elevated expression is thought to be due to increased transcription of the 
PKC gene by autocrine VEGF stimulation (Abrams, et al., 2010). Furthermore, PKCII is 
constitutively active in CLL cells and contributes to cell survival by protecting the cells from 
pro-apoptotic BCR signalling (Abrams, et al., 2007). The importance of PKC in CLL 
development and propagation was more recently shown in a study using a CLL mouse 
model where the T-cell leukaemia (TCL1) protein is specifically overexpressed in B cells 
(Holler, et al., 2009). This particular mouse model of CLL develops an aggressive disease that 
is similar to the aggressive form of CLL in humans (Yan, et al., 2006). Thus, when this TCL1 
transgenic mouse model of CLL was crossed with mice in which PKC was disrupted it was 
found that the CLL-like disease did not develop (Holler, et al., 2009) (Figure 4A). 
Interestingly, in this same study the TCL1 transgenic PKC(+/-) heterozygous mice 
developed the CLL like disease with a slower kinetic than did TCL1 transgenic PKC wild 
type mice. Taken together, these data indicate that not only is PKC expression important 
for the development of CLL, but the level of expression plays a key role too. This same 
study also showed that the specific PKC inhibitor enzastaurin induced apoptosis of human 
CLL cells in vitro, suggesting that PKC was important in maintaining CLL cell survival. 
Signals through the BCR are important for CLL cell survival and PKCII activity inversely 
correlates with CLL cell response to BCR engagement (Abrams, et al., 2007). An important 
substrate of PKC in B cells is Bruton’s tyrosine kinase (Btk). Phosphorylation of Btk on 
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serine 180 results in its removal from the cell membrane and downregulation of its 
contribution to BCR signal transduction (Kang, et al., 2001) (Figure 4B). During BCR 
signalling PKC is downstream of Btk activation, therefore, PKC acts in a feedback fashion 
to provide inhibition of this signalling. In CLL cells, PKCII activity provides inhibition of 
BCR-induced intracellular calcium release and other downstream signals. We believe that 
this effect is largely pro-survival because strong, pro-apoptotic BCR signals would be 
largely suppressed in these cells. However, in CLL cells with high levels of PKCII activity 
the pro-survival effects of BCR signalling are lost. Experiments comparing cell survival and 
Mcl-1 protein levels have shown that both these parameters are increased in response to 
BCR signalling in CLL cells with low levels of PKCII activity, whereas there was little effect 
on these parameters when CLL cells with high levels of PKCII activity were stimulated by 
BCR engagement. The regulation of PKC activity in CLL cells is likely to involve factors 
such as VEGF and bFGF, which have been shown to increase PKC activity and 
downregulate BCR signalling (Abrams, et al., 2010). 
In addition to its role in downregulating BCR signalling in CLL cells, PKCII has also been 
shown to augment anti-apoptotic BCR signalling pathways in CLL cells (Barragan, et al., 
2006;zum Buschenfelde, et al., 2010). The expression of ZAP70 in CLL cells is associated with 
poor disease prognosis and it is thought to enhance BCR signal transduction by acting as a 
platform to recruit downstream signalling proteins (Chen, et al., 2005). In CLL cells, ZAP70 
was recently demonstrated to enhance the BCR signal by recruiting PKCII into lipid raft 
domains (zum Buschenfelde, et al., 2010). Here, PKCII becomes active and is shuttled to the 
mitochondrial membrane where it is able to phosphorylate anti-apoptotic Bcl-2 and pro-
apoptotic BimEL (Figure 4B). This process provides important pro-survival signals because 
phosphorylation of Bcl-2 increases its ability to sequester BimEL and promote cell survival, 
whilst the phosphorylation of BimEL results in its proteasomal degradation and protection 
from its pro-apoptotic effects (zum Buschenfelde, et al., 2010). Another example of how 
PKCII mediates BCR-induced survival signals in CLL cells is by activating Akt, a kinase 
that provides an important source of survival signals to CLL cells (Barragan, et al., 
2006;Longo, et al., 2008) (Figure 4B).    
Finally, one study has shown that PKCII may provide pro-survival signals in B cells by 
inducing the activation of Akt following stimulation by B cell-activating factor (BAFF) 
(Patke, et al., 2006). This may be important for the pathophysiology of CLL cells because 
both BAFF and Akt are important sources of pro-survival signals for CLL cells (Barragan, 
et al., 2006;Nishio, et al., 2005). In B cells, PKCII also transmits BCR signals to the NFB 
pathway by phosphorylating CARMA1, which, together with MALT1, Bcl10 and TAK1 
acts to stimulate I-B kinase activity and NFB pathway activation (Shinohara, et al., 
2005, 2007). Again, this may be pathophysiologically important in CLL because 
constitutive activation of the NFB pathway is a feature of the malignant cells of this 
disease (Hewamana, et al., 2008). Support for this idea comes from studies of diffuse 
large B cell lymphoma. PKC has been shown to be a therapeutic target in the malignant 
cells of this disease that bear the activated B cell phenotype because of the role it plays in 
activating the NFB pathway through the CARMA1/MALT1/Bcl10 complex (Naylor, et 
al., 2011). Taken together, these studies provide strong support for PKCII in 
maintaining CLL cell survival by decreasing pro-apoptotic signals and increasing anti-
apoptotic signals. 
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Fig. 4. PKC isoforms in CLL. (A) The T-cell leukaemia-1 (TCL1) mouse overexpresses TCL1 
protein and develops an aggressive disease similar to aggressive CLL. TCL1 mice that do 
not express PKC (PKC┚-/-) do not develop the CLL-like disease. (B) PKC┚II signalling. 
CLL cells express elevated levels of PKC┚II, likely due to VEGF stimulation. High PKC┚II-
expressing CLL cases inhibit BCR-signalling by phosphorylating Btk on S180 which prevents 
its activation. Additionally, PKC┚II augments antiapoptotic signalling by inducing S69 
phosphorylation of BimEL and S70 phosphorylation of Bcl-2. Phosphorylation on these 
residues results in BimEL proteasomal degradation, and sequestration of BimEL by Bcl-2, 
respectively. PKC┚II can also activate Akt which is an important mediator of CLL-cell 
survival. (C) Tumour suppressive effects of PKC┙ in CLL. When fetal-derived hematopoietic 
progenitor cells (HPCs) overexpressing a dominant negative form of PKC┙ (PKC┙-KR) are 
induced to differentiate into B lineage cells, a population of CLL-like malignant cells is 
generated. (D) PKC├ signalling. PKC├ is constitutively active in CLL cells via a PI3K├-
sensitive mechanism. Active PKC├ induces Akt phosphorylation which can then 
phosphorylate GSK3┚. Hyperphosphorylated GSK3┚ is inactive, preventing it from 
phosphorylating Mcl-1 and inducing its proteasomal degradation. PKC├ may also induce 
the transcription of Mcl-1 and XIAP. More recent work has shown that PKC├ can induce the 
expression of CD23 by activating NOTCH2.  
2.3.3 PKC 
Expression and function of PKC is associated with both tumour promoting and tumour 
suppressing effects. For example, high levels of PKC expression are associated with breast, 
prostrate, gastric and brain cancers (Griner & Kazanietz, 2007;Michie & Nakagawa, 2005) 
whilst low levels of PKC expression are associated with cancers of epithelium, pancreas, 
colon and CLL (Abrams, et al., 2007;Alvaro, et al., 1997;Detjen, et al., 2000;Neill, et al., 2003). 
In its tumour promoting role PKC is typically associated with anti-apoptotic signalling 
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achieved through the ability of this kinase to phosphorylate Bcl-2 at the mitochondrial 
membrane and increase its ability to sequester Bim (Jiffar, et al., 2004;Ruvolo, et al., 1998). 
The tumour suppressive functions of PKC are unclear. It has been shown that PKC 
knockout mice spontaneously develop intestinal lesions with greater frequency than wild 
type littermate controls, and that the mitotic index of the malignant cells derived from the 
PKC knockout mice is greater than that of malignant cells derived from wild type mice 
(Oster & Leitges, 2006). However, the mechanism through which this happens remains 
undefined. 
With respect to CLL, a very interesting study by Nakagawa et al (Nakagawa, et al., 2006) has 
suggested that PKC may have important tumour suppressive effects in this disease (Figure 
4C). Using a system whereby fetal liver-derived hematopoietic progenitor cells (HPCs) are 
induced to differentiate into B lineage cells, this group show that stable overexpression of a 
dominant negative PKC (PKC-KR) leads to the generation of a population of malignant 
cells bearing a CLL phenotype (CD19hi, CD23+, CD5+, sIgMlo) (Figure 4C). This population 
of malignant cells, like human CLL cells, are arrested in G0/G1 phase of the cell cycle and 
have enhanced expression of Bcl-2 (Hanada, et al., 1993;Kitada, et al., 1998;Mariano, et al., 
1992). However, when these cells are injected into SCID mice they have an enhanced 
proliferative capacity over mock-transfected and non-transfected control populations. This 
effect was specific for PKC-KR because expression of other kinase dead PKC isoforms 
within the same system did not produce cells bearing the same phenotype (Michie & 
Nakagawa, 2006).  
This system as a model for CLL is interesting for the reason that the malignant cells it 
generates have a high resemblance to the human CLL phenotype, as well as to CLL-like cells 
in mouse models of the disease (Holler, et al., 2009;Nakagawa, et al., 2006). This is important 
because in virtually all mouse models of CLL there is expansion of the B1 population of cells 
prior to development of disease (Hamano, et al., 1998), and B1 cells in the mouse mainly 
derive from progenitor cells within the fetal liver (Dorshkind & Montecino-Rodriguez, 
2007). Importantly, where the B1 population is absent, such as in PKC knockout mice, CLL 
does not develop in mouse models of this disease (Holler, et al., 2009). Thus, by subverting 
the function of PKC, this group has created a system whereby malignant expansion of B1 
cells is promoted at the haematopoietic stage. Although this system may not represent the 
actual mechanism of CLL pathogenesis, it does reveal some important aspects within this 
mechanism. Since this system is easily manipulated at a genetic level, further study will 
provide important information on the tumour suppressive function of PKC not only in 
CLL cells, but in other cancers as well. 
2.3.4 PKC 
In normal B cells PKC plays a key role in mediating signals for cell survival in response to 
BAFF (Mecklenbrauker, et al., 2004). BAFF signalling is important for maintaining B cell 
survival in the periphery, particularly with respect to B cells that have become tolerant to 
autoantigens (Ota, et al., 2010). Thus, mice in which BAFF is overexpressed develop 
autoimmune diseases such as systemic lupus erythematosis because autoreactive B cells are 
able to escape tolerance (Stohl, et al., 2005). A similar situation is observed in mice where 
PKC expression is disrupted (Mecklenbrauker, et al., 2004), indicating a pro-apoptotic role 
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for this PKC isozyme within a process that maintains survival of tolerant B cells. The 
relationship of PKC to BAFF is illustrated by experiments showing that this cytokine 
prevents nuclear localization of this PKC isoform. The absence of BAFF-stimulated signals 
results in nuclear localisation of PKC where it contributes to phosphorylation of histone 
H2B at serine 14 and initiation of apoptosis (Mecklenbrauker, et al., 2004). Whether BAFF-
mediated signalling stimulates pro-survival functions of PKC or merely prevents nuclear 
localisation is not clear at the present time, however, the pro-survival signalling capabilities 
of PKC, particularly those potentially induced by BAFF, may be highly relevant for CLL 
cells.  
A potential role of PKC in maintaining CLL cell survival was first proposed in a paper by 
Ringshausen et al. (Ringshausen, et al., 2002, 2006). This paper demonstrated that PKC was 
constitutively active in a phosphatidylinositol 3 kinase (PI3K)-dependent manner in CLL 
cells, and that inhibition of this isozyme with rottlerin induced apoptosis of treated cells by 
reducing the expression of Mcl-1 and XIAP (Ringshausen, et al., 2002, 2006) (Figure 4D). 
However, with respect to this latter aspect there are some controversies regarding the use of 
rottlerin. Rottlerin is described as a specific inhibitor of PKC, but its pro-apoptotic activity 
is associated with PKC-independent effects (Villalba, et al., 1999), particularly with respect to 
the uncoupling and depolarization of mitochondrial membranes (Soltoff, 2007). This 
uncoupling in cells leads to a reduction in ATP levels and consequent activation of 5'-AMP-
activated protein kinase (AMPK), with the end result resembling that produced by direct 
inhibition of PKC. Therefore, results using this inhibitor lack specificity and must be 
approached with caution. Nevertheless, there is evidence linking PI3K activity to PKC in B 
cells. BAFF signalling in B cells is impaired by the absence of the p110 isoform of PI3K 
(Henley, et al., 2008), and inhibition of PI3K with a compound known as CAL101 has 
shown clinical efficacy both in vitro and in vivo in CLL cells (Herman, et al., 2010, 
2011;Hoellenriegel, et al., 2011). Moreover, other recent findings have shown that PKC 
regulates CLL cell survival by activating the Akt pathway and stabilising the expression of 
Mcl-1 (Baudot, et al., 2009) (Figure 4D). These findings provide confirmation that PKC may 
play an anti-apoptotic role in CLL cells.  
Our own work has discovered that PKC may be important for the survival of CLL cells 
through its ability to phosphorylate STAT3 on serine 727, and cause increased transcription 
of the gene for Mcl-1 (Allen, et al., 2011) (Figure 4D). We found that treatment of CLL cells 
with Bis-1, a specific inhibitor of the novel isoforms PKC and PKC, inhibited the 
phosphorylation of STAT3S727 and decreased the expression of Mcl-1. Conversely, treatment 
with bryostatin, to activate classical and novel PKC isoforms, induced STAT3S727 
phosphorylation and increased Mcl-1 expression in CLL cells. Of course, the identity of the 
PKC isoform phosphorylating STAT3 in CLL cells remains to be characterised by more 
specific investigations, such as siRNA-mediated knock down of specific PKC isoform 
expression. Indeed, investigation of the mechanism of Syk-mediated CLL cell survival used 
siRNA to knock down PKC expression and showed a concomitant downregulation of Mcl-
1 expression (Baudot, et al., 2009). This study does not address whether PKC can 
phosphorylate STAT3 in CLL cells, but studies using other cell types have shown that PKC 
and PKC can perform this function (Aziz, et al., 2010;Gartsbein, et al., 2006). Thus, there is 
ample support for our findings that these PKC isoforms may promote CLL cell survival by 
activating STAT3-mediated Mcl-1 transcription. Such a mechanism may be useful 
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therapeutically. High expression levels of Mcl-1 correlate with more aggressive and poor 
prognosis disease in CLL by providing the malignant cells with protection against 
chemotherapy (Pepper, et al., 2008). Inhibiting PKC may reduce Mcl-1 expression in CLL 
cells, thereby lowering the apoptosis threshold and making them more susceptible to other 
chemotherapeutic agents.  
Another way in which PKC may contribute to CLL cell pathophysiology is through 
NOTCH2. One study has used RNAi to knock down PKC expression in CLL cells and 
found that this procedure antagonises PMA-induced NOTCH2 activation (Hubmann, et al., 
2010). This result is important because one characteristic of CLL cells is high expression of 
CD23, and NOTCH2 is known to regulate CD23 expression in these cells (Hubmann, et al., 
2002). Taken together, these results suggest that PKC and NOTCH2 are critically involved 
in maintaining the malignant phenotype of CLL cells.  
2.3.5 Other PKC isoforms 
The function of the remaining PKC isoforms in CLL cells remains poorly defined. However, 
their role in other cell types is well documented and may provide clues as to what function 
they have in CLL cells. Intriguingly, PKC is known to phosphorylate and activate 
signalling proteins such as Akt (Matsumoto, et al., 2001), PKD (Waldron & Rozengurt, 2003) 
and STAT3 (Aziz, et al., 2010), pathways which all provide an important source of anti-
apoptotic signals to CLL cells. Furthermore, in hairy cell leukaemia, PKC is activated by 
nitration of a tyrosine residue causing it to co-localise with ERK1/2 at the mitochondrial 
membrane and induce activation of the MAPK pathway (Slupsky, et al., 2007). Given that 
ERK1/2 has been shown to phosphorylate and stabilise the expression of Mcl-1 (Domina, et 
al., 2004), its activation in CLL cells may provide additional anti-apoptotic signals to CLL 
cells. Moreover, knockout mouse models have highlighted the importance of the atypical 
PKC in B-cell survival and proliferation by regulating the activation of ERK and NFB 
signalling pathways (Martin, et al., 2002).  
The above findings are important because Akt, NFB and STAT3 signalling pathways are 
known to be constitutively active in CLL cells, and because these pathways are essential in 
maintaining CLL cell viability (Allen, et al., 2011;de Frias, et al., 2009;Hazan-Halevy, et al., 
2010;Hewamana, et al., 2008;Zhuang, et al., 2010). The level of NFB activation is regarded as 
an essential component of CLL survival because it correlates with in vitro survival of CLL 
cells as well as with clinical disease progression (Hewamana, et al., 2008). Furthermore, our 
own work has demonstrated that STAT3 mediates CLL cell survival by inducing Mcl-1 
transcription (Allen, et al., 2011), and more recent studies have shown that both pathways 
can work in concert to induce the expression of anti-apoptotic proteins (Liu, et al., 2011). 
Collectively, these findings highlight that PKC has the potential to activate numerous anti-
apoptotic pathways and that further work is now critical to help understand the specific role 
these isoforms play in CLL cell signalling.  
2.4 CLL cell microenvironment and PKC 
It is clear that PKC-mediated signalling pathways seem to provide important survival 
signals to CLL cells in vitro, but how close do these conditions mimic those of in vivo? The 
CLL microenvironment is a milieu rich in signals generated by the interaction of the 
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malignant cells with IL-6 (Moreno, et al., 2001), IL-4 (Dancescu, et al., 1992) , SDF-1 (Burger, 
et al., 2000), BAFF and April (Endo, et al., 2007). These cytokines have all been shown to have 
anti-apoptotic effects on CLL cells. Moreover, the interaction of CLL cells with bone marrow 
stromal cells (Lagneaux, et al., 1998;Panayiotidis, et al., 1996), follicular dendritic cells 
(Pedersen, et al., 2002), endothelial cells (Moreno, et al., 2001), nurse-like cells (Burger, et al., 
2000) and CD40L-expressing cells (Hallaert, et al., 2008) results in an increase apoptotic 
threshold. This may be due to the induction of anti-apoptotic genes by these interactions; a 
comparison of the apoptosis regulatory genes and proteins in neoplastic B cells derived 
from CLL lymph node proliferation centres and peripheral blood found that lymph node-
derived cells had increased expression of anti-apoptotic Mcl-1, Bcl-XL and A1/Bfl-1 (Smit, et 
al., 2007). Moreover, co-culture of CLL cells on CD40L-expressing fibroblasts strongly 
induces the expression of these anti-apoptotic proteins, and this culminates in drug 
resistance (Hallaert, et al., 2008). PKC activation is likely to play a role in all of the 
microenvironmental interactions CLL cells are likely to encounter in an in vivo setting. 
However, whether inhibition of PKC lowers the threshold of apoptosis in CLL cells within 
their microenvironment is unknown and requires proper assessment before PKC inhibition 
becomes a therapeutic target in the treatment of this disease. Recent studies have begun to 
address this area and have demonstrated the importance of PKC in the survival of CLL cells 
that have been co-cultured with accessory cells (Martins, et al., 2011).  
3. Conclusion 
There are convincing demonstrations that PKC-mediated signalling is an important 
contributor to the development and propagation of the malignant clone in CLL. Inhibition of 
PKC, therefore, poses an attractive therapeutic approach for the treatment of this 
debilitating disease, particularly when we consider the roles of the individual PKC isozymes 
in CLL pathobiology. Within this review we have addressed the potential functions of 
PKC, ,  and, to a lesser extent, PKC and PKC. There is clear contribution of PKC to 
the pathogenesis of CLL, because disruption of PKC expression blocks the development of 
the CLL-like disease in TCL1-transgenic mice. This same type of experiment now needs to 
be done for the other PKC isoforms. Thus, disruption of PKC may accelerate disease 
progression in TCL1 mice because of the tumour suppressive action of this PKC isoform. 
The effect of PKC disruption is harder to predict. On one hand, disruption of PKC should 
accelerate disease development because the pro-apoptotic effects of this isoform would be 
lost. However, this prediction does not take into account the pro-survival functions of PKC 
in CLL cells, particularly its potential role in regulating STAT3 phosphorylation and Mcl-1 
protein expression. Finally, targeted disruption of PKC isoforms would potentially yield 
useful information on the role these isoforms play in CLL cell–microenvironment 
interactions.  
Within this review we have not addressed opposing functions of different PKC isoforms. 
For example, PKC and PKC can act antagonistically to regulate cellular proliferation and 
apoptosis in glioma cells (Mandil, et al., 2001). It is conceivable that more general inhibitors 
of PKC, through their ability to inhibit tumour suppressive or pro-apoptotic functions of 
PKC, may have an adverse effect by actually promoting CLL cell survival and proliferation. 
Nevertheless, PKC inhibitors such as N-benzoyl-staurosporine (PKC412) have already been 
tested in clinical trials, and were found to be effective at inducing CLL cell apoptosis in 
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patients that were refractory to fludarabine and chlorambucil (Ganeshaguru, et al., 2002). 
Furthermore, a more recent drug called sotrastaurin (AEB071) has been introduced as an 
immunosuppressant following organ transplant, and for the treatment of psoriasis. Early 
clinical trials suggest sotrastaurin has no clinically relevant side effects and has the potential 
to become a long term treatment option (Skvara, et al., 2008). Another study has suggested 
that AEB071 may even be useful in the treatment of diffuse large B-cell lymphoma (DLCBL) 
through inhibition of BCR-mediated NFB pathway activation (Naylor, et al., 2011). Thus, 
given the potential role of PKC in regulating CLL cell survival and disease pathogenesis and 
that side effects associated with the use of some inhibitors can be adequately managed 
within a clinical setting, PKC inhibitors may have therapeutic application in the treatment of 
CLL.  
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